Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

This phase IV trial compares the effect of premedication regimens with methylprednisolone versus dexamethasone for the prevention of allergic reaction to motixafortide in patients with multiple myeloma (MM) undergoing stem cell mobilization. MM patients that receive an autologous stem cell transplantation (ASCT) have better outcomes. However, not all MM patients are able to have a successful stem cell mobilization and collection which is needed to proceed to ASCT. The addition of motixafortide prior to stem cell mobilization has allowed more MM patients to collect the needed number of stem cel

Trial Details

NCT ID
NCT07101445
Phase
PHASE4
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Acetaminophen
  • Biospecimen Collection
  • Dexamethasone
  • Electronic Health Record Review
  • Famotidine
  • Loratadine
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Patients must be aged 18 years or older.
  • Patient must understand and voluntarily signed an informed consent form.
  • Patient must be willing and able to adhere to the study schedule and other protocol requirements.
  • Histologically confirmed multiple myeloma prior to enrollment and randomization.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →